C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey et al., AHA Guideline for the Management of Heart Failure A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, ACCF Circulation. 15 oct, vol.128, issue.16, pp.240-327, 2013.

P. Ponikowski, A. Voors, S. Anker, H. Bueno, J. Cleland et al., 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy The Cardiomyopathy Trial (CAT). Circulation, Eur Heart J. 20 mai Bänsch D, vol.3105, issue.2612, pp.1453-1461, 2002.

S. Strickberger, J. Hummel, T. Bartlett, H. Frumin, C. Schuger et al., Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia?AMIOVIRT Prophylactic Defibrillator Implantation in Patients with Nonischemic Dilated Cardiomyopathy, J Am Coll Cardiol. 21 mai N Engl J Med, vol.41350, issue.2021, pp.2151-2159, 2003.

G. Bardy, K. Lee, D. Mark, J. Poole, D. Packer et al., Amiodarone or an Implantable Cardioverter???Defibrillator for Congestive Heart Failure, New England Journal of Medicine, vol.352, issue.3, pp.225-262, 2005.
DOI : 10.1056/NEJMoa043399

Y. Pinto, P. Elliott, E. Arbustini, Y. Adler, A. Anastasakis et al., Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies, Eur Heart J. 20 janv Br Heart J. déc, vol.72744, issue.86, pp.672-675, 1980.

P. Elliott, B. Andersson, E. Arbustini, Z. Bilinska, F. Cecchi et al., Classification of Cardiomyopathies, ):270?6. 10. ?ahan E,564?72. 12. Rakar S, pp.117-140, 1989.
DOI : 10.1016/j.jacc.2013.10.008

J. Goldberger, M. Taylor, P. Fain, G. Sinagra, M. Robinson et al., Sudden cardiac death risk stratification in dilated cardiomyopathy: climbing the pyramid of knowledge Natural history of dilated cardiomyopathy due to lamin A/C gene mutations, Circ Arrhythm Electrophysiol. déc J Am Coll Cardiol. 5 mars, vol.741, issue.145, pp.771-80, 2003.

M. Ackerman, S. Priori, S. Willems, C. Berul, R. Brugada et al., EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience, 1077?109. 16. van Spaendonck, pp.628-664, 2011.

E. Arbustini, A. Pilotto, A. Repetto, M. Grasso, A. Negri et al., Autosomal dominant dilated cardiomyopathy with atrioventricular block: a lamin A/C defect-related disease, Journal of the American College of Cardiology, vol.39, issue.6, pp.981-90, 2002.
DOI : 10.1016/S0735-1097(02)01724-2

O. Akinrinade, L. Ollila, S. Vattulainen, J. Tallila, M. Gentile et al., Genetics and genotype???phenotype correlations in Finnish patients with dilated cardiomyopathy, European Heart Journal, vol.36, issue.34, pp.2327-2364, 2015.
DOI : 10.1093/eurheartj/ehv253

J. Berlo, . Van, W. Voogt, . De, A. Kooi et al., Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death? Clinical and Functional Characterization of a Novel Mutation in Lamin A/C Gene in a Multigenerational Family with Arrhythmogenic Cardiac Laminopathy, 79?83. 20. Forleo C, p.2015, 2004.

M. Pasotti, C. Klersy, A. Pilotto, N. Marziliano, C. Rapezzi et al., Long-Term Outcome and Risk Stratification in Dilated Cardiolaminopathies Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers: A European Cohort Study Risk prediction of ventricular arrhythmias and myocardial function in Lamin A/C mutation positive subjects, 1250?60. 22. van Rijsingen IAW493?500. 23. Hasselberg NE, pp.563-71, 2008.

P. Lancellotti, D. Muñoz, V. Aboyans, R. Asteggiano, and M. Galderisi, 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines, Risk Factors for Doxorubicin-lnduced Congestive Heart Failure):710?7. 25. Zamorano JL, pp.211-237, 1979.

M. Wasielewski, K. Van-spaendonck-zwarts, N. Westerink, J. Jongbloed, A. Postma et al., Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy Open Heart Underlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy Alcohol abuse and heart failure Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians Tachycardia-induced cardiomyopathy, ):1801?15. 28. Felker GM1638?50. 30. Laonigro I,944?50. 32. Guzzo-Merello G al. Natural History and Prognostic Factors in Alcoholic Cardiomyopathy, pp.453-62, 1999.

P. Geelen, M. Goethals, B. De-bruyne, P. Brugada, S. Lafitte et al., A prospective hemodynamic evaluation of patients with chronic atrial fibrillation undergoing radiofrequency catheter ablation of the atrioventricular junction Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation, Am J Cardiol. 15 déc Circulation. 8 nov, vol.80112, issue.12, pp.2896-903, 1997.

L. Hsu, P. Jaïs, P. Sanders, S. Garrigue, M. Hocini et al., Catheter Ablation for Atrial Fibrillation in Congestive Heart Failure, New England Journal of Medicine, vol.351, issue.23, pp.2373-83, 2004.
DOI : 10.1056/NEJMoa041018

L. Cooper and . Myocarditis, Myocarditis, New England Journal of Medicine, vol.360, issue.15, pp.1526-1564, 2009.
DOI : 10.1056/NEJMra0800028

J. Magnani, G. Dec, A. Caforio, S. Pankuweit, E. Arbustini et al., Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Cardiovascular magnetic resonance in myocarditis: A JACC White Paper, Diagnosis and Treatment. Circulation. 14 févr1475?87. 41. Mason JW, pp.269-75, 1995.

M. Anzini, M. Merlo, G. Sabbadini, G. Barbati, G. Finocchiaro et al., Long-Term Evolution and Prognostic Stratification of Biopsy-Proven Active Myocarditis. Circulation. 26 nov 2013 Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis, N Engl J Med. 9 mars, vol.128342, issue.2210, pp.2384-94, 2000.

M. Francone, K. Broch, A. Andreassen, E. Hopp, T. Leren et al., Role of cardiac magnetic resonance in the evaluation of dilated cardiomyopathy: diagnostic contribution and prognostic significance Results of comprehensive diagnostic work-up in 'idiopathic' dilated cardiomyopathy. Open Heart. 10 janv 2015 Dilated (congestive) cardiomyopathy. Follow-up study of 137 patients, ISRN Radiol. G Ital Cardiol. juill, vol.2014214, issue.17, pp.365404-365449, 1984.

M. Merlo, A. Pivetta, B. Pinamonti, D. Stolfo, M. Zecchin et al., Long-term prognostic impact of therapeutic strategies in patients with idiopathic dilated cardiomyopathy: changing mortality over the last 30 years ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 Guidelines in review: 2013 ACCF/AHA Guideline for the Management of Heart Failure Results of comprehensive diagnostic work-up in 'idiopathic, 317?24. 48. Authors/Task Force Members,803?69. 49. Gupta A, 2012.

A. Cooper, L. Baughman, K. Feldman, A. Frustaci, A. Jessup et al., An Executive Summary The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the Ventricular arrhythmias in idiopathic dilated cardiomyopathy):195?201. 54. Liuba I, Marchlinski FE. The substrate and ablation of ventricular tachycardia in patients with nonischemic cardiomyopathy Natural history of dilated cardiomyopathy due to lamin A/C gene mutations Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure Nonsustained ventricular tachycardia in severe heart failure, 2216?33. 53. von Olshausen K):3198?203. 58. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking, pp.1589-97, 1984.

S. Priori, C. Blomström-lundqvist, A. Mazzanti, N. Blom, M. Borggrefe et al., 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death Multiple Autonomic and Repolarization Investigation of Sudden Cardiac Death in DilatedCardiomyopathy and Controls, 1101?8. 61. Nazarian S, Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 1 nov, pp.2821-2826, 2005.

K. Wu, R. Weiss, D. Thiemann, K. Kitagawa, A. Schmidt et al., T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy, 2414?21. 63. aus dem Siepen F, pp.210-216, 2008.

R. Assomull, S. Prasad, J. Lyne, G. Smith, E. Burman et al., Prognosis in Dilated Cardiomyopathy Angiotensin Receptor Antagonists to Prevent Sudden Death in Heart Failure: Does the Dose Matter? ISRN Cardiol 6 févr 2014 66. Group* TCTS. Effects of Enalapril on Mortality in Severe Congestive Heart Failure Investigators* TS. Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions OVerview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure, 685?91. 68. Garg R,1450?6. 69. Investigators* TS. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-convertingenzyme inhibitors: the CHARM-Alternative trial, pp.293-302, 1987.

B. Pitt, R. Segal, F. Martinez, G. Meurers, A. Cowley et al., Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both, 1893?906. 74. Hjalmarson A Effects of controlledrelease metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 8 mars, pp.747-52, 1997.

B. Pitt, F. Zannad, W. Remme, R. Cody, A. Castaigne et al., Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) Eur J Heart Fail Effect of the angiotensinreceptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients A Comparison of Antiarrhythmic-Drug Therapy with Implantable Defibrillators in Patients Resuscitated from Near-Fatal Ventricular Arrhythmias Canadian Implantable Defibrillator Study (CIDS) A Randomized Trial of the Implantable Cardioverter Defibrillator Against Amiodarone Randomized Comparison of Antiarrhythmic Drug Therapy With Implantable Defibrillators in Patients Resuscitated From Cardiac Arrest al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials, Randomized Aldactone Evaluation Study Investigators11?21. 771990?7. 79. Investigators TA versus ID (AVID)1576?84. 80. Connolly SJ,1297?302. 81. Kuck K748?54. 82. Connolly SJ Cardiac-Resynchronization Therapy with or without an Implantable Defibrillator in Advanced Chronic Heart Failure, pp.709-726, 1997.

J. Cleland, J. Daubert, E. Erdmann, N. Freemantle, D. Gras et al., Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events Rate, causes, and impact on patient outcome of implantable device complications requiring surgical revision: large population survey from two centres in Italy. Europace. 1 avr 2013 Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark A systematic review of ICD complications in randomised controlled trials versus registries: is our 'real-world' data an underestimation? Open Heart 17 févr 2015 89 Generator and Lead-Related Complications of Implantable Cardioverter Defibrillators Implantation-Related Complications of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy Devices: A Systematic Review of Randomized Clinical Trials Meta-Analysis of Bleeding Complications Associated with Cardiac Rhythm Device Implantation al. Frequency of inappropriate therapy in patients implanted with dual-versus single-chamber ICD devices in the ICD arm of MADIT-CRT, 1329?38. 86. Palmisano P66?70. 90. van Rees JB995?1000. 91468?74. 92. Ruwald A-CH672?9. 93. Sandgren E, Rorsman C, Engdahl J, Edvardsson N. Low rate of and rapid attention to inappropriate ICD shocks with remote device and rhythm monitoring: a qualitative study. Open Heart 27 juill 2015 94, 2005.

J. Arribas, Analyses of inappropriate shocks in a Spanish ICD primary prevention population: Predictors and prognoses guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death? executive summary, Int J Cardiol. 15 sept Eur Heart J. 1 sept, vol.19527, issue.17, pp.2099-140, 2006.

M. Moretti, M. Merlo, G. Barbati, D. Lenarda, A. Brun et al., Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease Predictors and outcome of sustained improvement in left ventricular function in dilated cardiomyopathy Long-term outcome in patients with congestive heart failure and intact systolic left ventricular performance Positive Response to Cardiac Resynchronization Therapy Reduces Arrhythmic Events After Elective Generator Change in Patients with Primary Prevention CRT-D Differentiation of Heart Failure Related to Dilated Cardiomyopathy and Coronary Artery Disease Using Gadolinium-Enhanced Cardiovascular Magnetic Resonance, Prognostic impact of familial screening in dilated cardiomyopathy):195?201. 98. Blechman I,1212?6. 100. Sebag FA,1368?75. 101. McCrohon54?9. 102. Holmström M, Kivistö S, Heliö T, Jurkko R, Kaartinen M, Antila M, et al. Late gadolinium enhanced cardiovascular magnetic resonance of lamin A/C gene mutation related dilated cardiomyopathy. J Cardiovasc Magn Reson Off J Soc Cardiovasc Magn Reson, pp.30-103, 1992.

E. Sueyoshi, I. Sakamoto, M. Uetani, D. Unverferth, P. Baker et al., Myocardial delayed contrast-enhanced MRI: relationships between various enhancing patterns and myocardial diseases Evolution of a hereditary cardiac conduction and muscle disorder: a study involving a family with six generations affected ASsociation of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy, 691?7. 104. Graber HL,21?35. 105. Gulati A896?908. 106. Fatkin D, Otway R, Richmond Z. Genetics of dilated cardiomyopathy, pp.129-169, 1986.

R. Begay, S. Graw, G. Sinagra, M. Merlo, D. Slavov et al., Role of Titin Missense Variants in Dilated Cardiomyopathy, Journal of the American Heart Association, vol.4, issue.11
DOI : 10.1161/JAHA.115.002645

R. Hershberger, J. Lindenfeld, L. Mestroni, C. Seidman, M. Taylor et al., Genetic Evaluation of Cardiomyopathy???A Heart Failure Society of America Practice Guideline, Journal of Cardiac Failure, vol.15, issue.2, pp.83-97, 2009.
DOI : 10.1016/j.cardfail.2009.01.006

Y. Choi, S. Kim, S. Lee, S. Chang, S. Jang et al., Quantification of left ventricular trabeculae using cardiovascular magnetic resonance for the diagnosis of left ventricular non-compaction: evaluation of trabecular volume and refined semi-quantitative criteria Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: diagnostic accuracy of late gadolinium enhancement):101?8. 111. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial, 9?13. 112. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet Lond Engl. 12 juin, pp.2001-2008, 1999.

B. Pitt, P. Poole-wilson, R. Segal, F. Martinez, K. Dickstein et al., Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II Medical therapy versus implantable cardioverter -defibrillator in preventing sudden cardiac death in patients with left ventricular systolic dysfunction and heart failure: a meta-analysis of > 35,000 patients, Lancet Lond Engl. 6 mai Int J Cardiol, vol.355173, issue.2, pp.197-203, 2000.

C. Witt, M. Kronborg, E. Nohr, P. Mortensen, C. Gerdes et al., Optimization of heart failure medication after cardiac resynchronization therapy and the impact on long-term survival Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: A meta-analysis of randomized controlled trials, 182?8. 116. Desai AS, pp.2874-2883, 2004.

S. Ahsan, B. Saberwal, P. Lambiase, S. Chaubey, O. Segal et al., An 8-year singlecentre experience of cardiac resynchronisation therapy: procedural success, early and late complications, and left ventricular lead performance Cardiac-resynchronization therapy for the prevention of heart-failure events, 711?7. 118. Moss AJ, pp.1329-1367, 2009.

J. Sjöblom, T. Kalm, F. Gadler, L. Ljung, V. Frykman et al., Efficacy of primary preventive ICD therapy in an unselected population of patients with reduced left ventricular ejection fraction. Europace. 1 févr 2015 A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death Changing Characteristics and Mode of Death Associated With Chronic Heart Failure Caused by Left Ventricular Systolic Dysfunction A Study Across Therapeutic Eras. Circ Heart Fail, J Am Coll Cardiol. 30 sept, vol.17524, issue.1204, pp.255-61396, 2008.